


DOB:

Encounter Date:

MRN:

Physician
Specialty: Internal Medicine

Progress Notes 
Signed

Encounter Date:

Follow up is a year old male. Patient presents with:

Video Visit Consent::

The patient has given verbal or written consent for delivery of health care, via telehealth through a Video Visit appointment.

Patient was using real-time Telehealth tools between my location and the patient's location which is confirmed to be in California. Prior to discussing medical issues, the patient provided informed verbal consent to perform this consultation using Telehealth tools, and all questions about the Telehealth interaction were answered.

- Patient confirms they are located in a safe location and within the state of California: YES
- Patient states location at time of video visit is:
- Patient confirmed date of birth and the phone number where they can be reached in case video visit is disconnected.

In accordance with federal, state, and institutional recommendations to reduce person-to-person contact during the ongoing outbreak of Coronavirus, a scheduled in-person clinic visit was reformatted to a telehealth consultation.

HPI: Medications and laboratory reviewed, health care management addressed

Current Outpatient Medications

Medication	Sig	Dispense	Refill
• metoprolol succinate ER (TOPROL XL) 25mg 24Hr-XL Tab	Take 1 Tab by mouth daily		
• Icosapent Ethyl (VASCEPA) 1 g CAPS	Take 2 g by mouth twice daily with breakfast and dinner	360 Cap	1
• allopurinol (ZYLOPRIM) 300mg Tab	Take one Tab by mouth daily	90 Tab	3
• ALPRAZolam (XANAX) 0.25mg Tab	Take one Tab by mouth three times daily as needed for	20 Tab	0

(MRN

) Printed by

at

(MR #) DOB: Encounter Date:

Anxiety/Restlessness

• metFORMIN 24Hr-XR (GLUCOPHAGE XR) 500mg Tab	TAKE 3 TABLETS (1,500 MG) BY MOUTH DAILY WITH EVENING MEAL	90 Tab	44
• rosuvastatin (CRESTOR) 40mg Tab	TAKE 1 TABLET BY MOUTH EVERY DAY	90 Tab	3
• colchicine (COLCRYS) 0.6mg Tab	Take 2 Tabs by mouth at the first sign of flare, followed in 1 hour with a single Tab by mouth for persistent pain. Max dose is 3 Tabs per day.	30 Tab	1
• aspirin EC (ECOTRIN) 81 MG Tab	Take 1 Tab by mouth daily	30 Tab	3

No current facility-administered medications for this visit.

Review of patient's allergies indicates no known allergies.

Telephone on

Component	D	Value	Ref Range	Status
• GLUCOSE, SERUM		90	65 - 99 mg/dL	Final
• BUN		16	6 - 24 mg/dL	Final
• CREATININE, SERUM		1.00	0.76 - 1.27 mg/dL	Final
• EGFR		87	>59 mL/min/1.73	Final
• BUN/CREATININE RATIO		16	9 - 20 NA	Final
• SODIUM, SERUM		142	134 - 144 mmol/L	Final
• POTASSIUM, SERUM		4.4	3.5 - 5.2 mmol/L	Final
• CHLORIDE, SERUM		105	96 - 106 mmol/L	Final
• CO2 (Bicarbonate)		21	20 - 29 mmol/L	Final
• CALCIUM, SERUM		9.6	8.7 - 10.2 mg/dL	Final
• PROTEIN, TOTAL, SERUM		7.2	6.0 - 8.5 g/dL	Final
• ALBUMIN, SERUM		4.8	3.8 - 4.9 g/dL	Final
• GLOBULIN, TOTAL		2.4	1.5 - 4.5 g/dL	Final
• A/G RATIO		2.0	1.2 - 2.2 NA	Final
• BILIRUBIN, TOTAL		0.4	0.0 - 1.2 mg/dL	Final
• ALKALINE PHOSPHATASE, S		74	44 - 121 IU/L	Final
• AST (SGOT)		37	0 - 40 IU/L	Final
• ALT (SGPT)		43	0 - 44 IU/L	Final
• CHOLESTEROL, TOTAL		134	100 - 199 mg/dL	Final
• TRIGLYCERIDES		187 (A)	0 - 149 mg/dL	Final
• HDL CHOLESTEROL		43	>39 mg/dL	Final
• VLDL Cholesterol Cal		31	5 - 40 mg/dL	Final
• LDL Chol Calc (NIH)		60	0 - 99 mg/dL	Final
• Comment:		CANCELED		Final
• HEMOGLOBIN A1C		5.8 (A)	4.8 - 5.6 %	Final
• ESTIM. AVG GLU (EAG)		120	mg/dL	Final
• URIC ACID, SERUM		3.9	3.8 - 8.4 mg/dL	Final
• Interpretation		Note		Final

Review of Systems:

The following systems were reviewed and were negative as pertains to the current presenting complaint, except as outlined in the HPI: DERM, EYES, ENT, CV, RESP, GI, GU/GYN/Sexual Concerns, MSK, NEURO, PSYCH, HEME/ENDO

PE:

Gen: Alert and in no acute distress.

Problem List:**Patient Active Problem List:**

- Hyperlipidemia
- SVT (supraventricular tachycardia) (CMS/HCC)
- Hypogonadism male
- Preventative health care
- HSV (herpes simplex virus) infection
- Perennial allergic rhinitis
- Extrinsic asthma without complication
- Glucose intolerance (impaired glucose tolerance)
- Essential hypertension
- Paroxysmal A-fib (CMS/HCC)
- Coronary artery disease
- Status post coronary artery bypass grafting

Encounter Diagnoses/Assessment/Plan:**Problem List Items Addressed This Visit**

Coronary artery disease

Relevant Orders

- CBC WITH AUTOMATED DIFFERENTIAL
- COMPREHENSIVE METABOLIC PANEL W GFR

Glucose intolerance (impaired glucose tolerance)

Relevant Orders

- HEMOGLOBIN A1C

Hyperlipidemia - Primary

Relevant Medications

- Icosapent Ethyl (VASCEPA) 1 g CAPS

Other Relevant Orders

- LIPID PROFILE

Preventative health care

Relevant Orders

- HEPATITIS B SURFACE AB, QUAL
- HEPATITIS B CORE ANTIBODY TOTAL
- HEPATITIS B SURFACE AG W REFLEX CONF IF INDICATED

RTO - 6 months

New orders ordered on this visit:

CBC WITH AUTOMATED DIFFERENTIAL [LABCBCA]
COMPREHENSIVE METABOLIC PANEL W GFR [LABCMPG]
LIPID PROFILE [LABLIPID]
HEMOGLOBIN A1C [LABGLYCO]
HEPATITIS B SURFACE AB, QUAL [LABHBSAB]
HEPATITIS B CORE ANTIBODY TOTAL [LABHBC]
HEPATITIS B SURFACE AG W REFLEX CONF IF INDICATED [LABHBSAG]
CBC WITH AUTOMATED DIFFERENTIAL [LABCBCA]
COMPREHENSIVE METABOLIC PANEL W GFR [LABCMPG]
LIPID PROFILE [LABLIPID]
HEMOGLOBIN A1C [LABGLYCO]
HEPATITIS B SURFACE AB, QUAL [LABHBSAB]
HEPATITIS B CORE ANTIBODY TOTAL [LABHBC]
HEPATITIS B SURFACE AG W REFLEX CONF IF INDICATED [LABHBSAG]

Medications Discontinued During This Encounter

metoprolol tartrate (LOPRESSOR) 25mg*
VASCEPA 1 g CAPS
Reason: Reorder - NO pharmacy notice and NO AVS printing

More than 13 minutes were spent either face to face with the patient or in case coordination, >50% of th time was spent counseling the patient.

Electronically signed by

Phone:
Fax:

Video Visit on Note viewed by patient





Additional Documentation

Flowsheets: [Patient-Reported Data, COVID-19 Immunization](#)
Encounter Info: [Billing Info, History, Allergies, Detailed Report](#)

Orders Placed



- ! HEMOGLOBIN A1C
- ! LIPID PROFILE
- 🧪 CARDIOVASCULAR RISK ASSESSMENT
- 🧪 CBC WITH AUTOMATED DIFFERENTIAL

(MR #) DOB: Encounter Date:


-  COMPREHENSIVE METABOLIC PANEL W GFR
-  HEPATITIS B CORE ANTIBODY TOTAL
-  HEPATITIS B SURFACE AB, QUAL
-  HEPATITIS B SURFACE AG W REFLEX CONF IF INDICATED

All Encounter Results

Medication Changes

-  Icosapent Ethyl 2 g Oral BID WITH BKFST AND DINNER ~~TAKE 2 CAPSULE BY MOUTH TWICE DAILY WITH BREAKFAST AND DINNER DISPENSE BRANDED ONLY~~
-  ~~Metoprolol Tartrate 25 mg Oral BID, Please schedule a follow up appointment with~~ *refills* *for additional*

Visit Diagnoses

-  Hyperlipidemia, unspecified hyperlipidemia type
 - Preventative health care
 - Glucose intolerance (impaired glucose tolerance)
 - Coronary artery disease, unspecified vessel or lesion type, unspecified whether angina present, unspecified whether native or transplanted heart

(MRN) Printed by at